GLP-1 Pill War: What Orforglipron Means for You (April 2026)
Eli Lilly's oral GLP-1 pill gets its FDA decision April 10. Novo Nordisk just launched Wegovy subscriptions at $249/month. Here's what's happening now.
Orforglipron — Eli Lilly's second-generation oral GLP-1 — sits at the center of a brewing competitive battle in 2026. With FDA decision dates pending, the medication is being closely watched by patients waiting for a more potent oral option.
Key takeaways
- Orforglipron showed Phase 3 weight loss closer to injectable semaglutide than to other oral options
- It does not require fasting, refrigeration, or special handling
- FDA decision is expected in Q2 2026
- Pricing is unannounced but expected to be competitive with Foundayo
Why orforglipron matters
It would be the first non-peptide oral GLP-1 to reach market. Non-peptide drugs are easier to manufacture, more stable in transit, and easier to formulate — all of which translates to lower cost and broader distribution if approved.
Trial data showed roughly 13–15% body-weight loss at 12 months, materially higher than other oral options to date.
What to do while you wait
Patients who are starting therapy now should not delay waiting for orforglipron — even a fast approval would not have it at retail until late 2026 at earliest. Patients on existing therapy should hold their plan and re-evaluate when launch pricing is published.